轮证日报|医药股走高,药明认购证涨100%
今日市场短评
港股延续反弹行情,恒指涨1.21%,6个交易日累计涨逾20%,重回22000点上方,恒生科技指数涨2.05%,盘中一度涨近5%。盘面上,大型科技股普遍造好,阿里巴巴、快手涨超7%,小米集团涨4%,百度、网易、美团皆有涨幅,京东尾盘转跌;电信设备股午后拉升领涨,中兴通讯午后复牌一度飙涨60%,收涨逾23%表现较为抢眼;受政策利好影响,氢能源股走强,教育股反弹明显,餐饮股、汽车股、军工股、半导体股、中医药股、大金融股纷纷上扬,蔚来汽车创上市新高。另一方面,电力板块逆势下跌明显,前期活跃的体育用品股全天萎靡,家电股、石油股、港口航运股普跌。
窝轮证焦点
药明生物(02269)
药明认购证(12341)
到期日:2022年7月
杠杆:4.85倍
高盛:药明生物去年业绩略胜预期,维持“买入”评级
高盛发研报指,药明生物去年销售额按年增长83.3%,较该行预测高出3.3%,纯利增长100%,亦略胜高盛预期。撇除一次性收益,核心盈利按年增长92.6%,毛利率提升至46.9%,主要受惠于疫情相关合约推高产能利用率。该行指,去年的强劲增长主要来自北美及欧洲客户,中国市场则放缓。
虽然投资者对资金投入及市场需求感到担忧,但高盛认为,药明积压订单增长强劲,整体及三年积压订单分别按年增长20.1%及98.2%,自2月8日起被美国列入“未经核实”实体名单后,更新增11个来自全球客户的项目。
高盛指,药明管理层一直在积极与美国商务部洽商,料将成为今年股价的关键催化剂,鉴于公司运营的持续强劲及积压订单增长进一步巩固基本面,重申“买入”评级,在微调2022至2023年盈利预测后,将目标价由112.2港元降至110.7港元。
牛熊证焦点
小米集团(01810)
小米牛证(53297)
到期日:2023年4月
回收价:13
杠杆:5.3倍
瑞信:维持小米集团跑赢大市评级 目标价22.5港元
瑞信表示,由于地缘政治紧张、持续的供应中断和安卓系统,将小米2022和2023年智能手机出货量预测下调7%至2.07亿元和2.28亿元人民币。该行维持小米评级“跑赢大市”,由于供应链受限和Android手机疲软,瑞信将小米2022和2023年每股盈利预测分别下调9%和11%,目标价由24.2港元下调至22.5港元。
瑞信认为,由于半导体供应恢复,由欧洲、拉丁美洲和东南亚推动的出货量将积压在下半年。瑞信预计 ,小米2022年互联网服务业务将在海外广告抵销国内互联网压力的推动下,按年增长19%,物联网可能会继续保持良好的增长。
衍生品资金流入/流出


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.